BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...
BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines ALAMEDA, Calif ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will ...
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, ...
Resource is expected to help researchers select the most suitable progenitor cell lines. Regenerative medicines firm BioTime has teamed up with XenneX to establish LifeMap Sciences, an intiiative that ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a ...
A look at the shareholders of BioTime Inc (NYSEMKT:BTX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a ...
This East Bay molecular diagnostics company shunned the traditional IPO route to go public on the market's first trading day of 2016. Its stock jumped on its first day of trading on Monday. An East ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results